Cardiovascular disorders in Parkinson's disease
https://doi.org/10.30629/2658-7947-2024-29-6-15-19
Abstract
Objective. To review the literature data on the comorbidity of cardiovascular disease with Parkinson’s disease (PD) and to evaluate the role of cardiovascular autonomic failure as a differential diagnostic criterion for synucleinopathy.
Material and methods. The search of scientific literature was performed in PubMed, ProQuest Dissertations & Theses Global databases, electronic library system of the Media Sphere publishing house from 2014 to the present and includes 42 relevant sources. The methodological premise of the study is the notion of the differentiating role of autonomic dysfunction symptoms in the diagnosis of PD at the premotor stage.
Conclusion. Autonomic cardiac denervation occurs at the premotor stage of PD and may be its primary manifestations. Patients with PD also develop other comorbid cardiovascular pathology: ischaemic heart disease, arrhythmias, cardiomyopathies and sudden cardiac death. Nosological substantiation of cardiovascular autonomic failure is crucial for providing specialised cardiological care to PD patients.
About the Authors
V. V. Yudina
V.I. Razumovsky Saratov State Medical University
Russian Federation
Russian Federation
Saratov
O. N. Voskresenskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Moscow
References
1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015; 30(12):1591–1601. https://doi.org/10.1002/mds.26424
2. Nodel M.R. Diagnostic criteria for Parkinson’s disease. Russian Journal of Geriatric Medicine. 2021;(1):92–96. https://doi.org/10.37586/2686-8636-1-2021-92-96 EDN ZQSALK.
3. Levin OS, Illarioshkin SN, Golubev VL. Extrapyramidal syndromes: a guide for physicians. Moscow: MED-press-Inform; 2022:769 p. (Russian). ISBN 978-5-907504-80-6.
4. Leys F, Wenning GK, Fanciulli A. The role of cardiovascular autonomic failure in the differential diagnosis of α-synucleinopathies. Neurol Sci. 2022;43(1):187–198. https://doi.org/10.1007/s10072-021-05746-6
5. Gusev EI, Blokhin VE, Vartanov SA, Martynov MU, Katunina EA, Alessenko AV, Denisova IA, Pavlova EN, Polterovich VM, Kucheryanu VG, Shupik MA, Nodel MR, Kalinkin AL, Sokolov SA, Chubarova TV, Shakleina MV, Pronina TS, Ugrumov MV. Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):9-20 (Russian). https://doi.org/10.17116/jnevro20211210119 EDN: MWPUWZ.
6. Ugrumov M. Development of early diagnosis of Parkinson’s disease: Illusion or reality? CNS Neurosci Ther. 2020;26(10):997–1009. https://doi.org/10.1111/cns.13429
7. Sharma VK, Sangwan NS. Chapter 6. Biotechnology applications in neurodegenerative diseases. In: Barh D, ed. Biotechnology in Healthcare: technologies and innovations. Academic Press; 2022;2:89–103. https://doi.org/10.1016/B978-0-323-90042-3.00005-0
8. AD/PD 2024: early diagnosis key for disease-modifying therapies in Parkinson’s. Clinical Trials Arena March 8, 2024. GlobalData Healthcare. https://www.clinicaltrialsarena.com/analyst-comment/ad-pd-2024-early-diagnosis-remains-a-hurdle-for-disease-modifying-therapies-in-parkinsons/ (the date of referring: 30.04.2024).
9. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan CW, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Chapin A, Douwes-Schultz D, Frank T, Goettsch F, Liu PY, Nandakumar V, Reitsma MB, Reuter V, Sadat N, Sorensen RJD, Srinivasan V, Updike RL, York H, Lopez AD, Lozano R, Lim SS, Mokdad AH, Vollset SE, Murray CJL. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090. https://doi.org/10.1016/S0140-6736(18)31694-5
10. United Nations, Department of Economic and Social Affairs, Population Division. World population ageing 2019: Highlights. ST/ESA/SER.A/430. New York: UN; 2020:60 p. https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf (the date of referring: 30.04.2024).
11. Fulop T, Larbi A, Khalil A, Cohen AA, Witkowski JM. Are We Ill Because We Age? Front Physiol. 2019;10:1508. https://doi.org/10.3389/fphys.2019.01508
12. Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J Clin Neurosci. 2018;53:1–5. https://doi.org/10.1016/j.jocn.2018.04.031
13. Kincl V, Panovský R, Bočková M, Rektor I, Mojica-Pisciotti ML, Máchal J. Parkinson´s disease cardiovascular symptoms: A new complex functional and structural insight. Eur J Neurol. 2024;31(2):e16110. https://doi.org/10.1111/ene.16110
14. Goldstein DS, Sharabi Y. The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res. 2019;1702:74–84. https:// doi.org/10.1016/j.brainres.2017.09.033
15. Yoo SW, Oh YS, Ryu DW, Ha S, Lyoo CH, Kim Y, Yoo JY, Kim JS. Cardiac sympathetic “morbidity” might reflect the neurobiology of early Parkinson’s disease. J Neurol. 2024;271(2):944–954. https://doi.org/10.1007/s00415-023-12049-7
16. Lee B, Edling C, Ahmad S, LeBeau FEN, Tse G, Jeevaratnam K. Clinical and Non-Clinical Cardiovascular Disease Associated Pathologies in Parkinson’s Disease. Int J Mol Sci. 2023;24(16):12601. https://doi.org/10.3390/ijms241612601
17. Gonçalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT. Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson’s Disease. Neuroscientist. 2022;28(6):530–542. https://doi.org/10.1177/1073858421990000
18. Grosu L, Grosu AI, Crisan D, Zlibut A, Perju-Dumbrava L. Parkinson’s disease and cardiovascular involvement: Edifying insights (Review). Biomed Rep. 2023;18(3):25. https://doi.org/10.3892/br.2023.1607
19. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic Nervous System Dysfunction: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1189–1206. https://doi.org/10.1016/j.jacc.2018.12.064
20. Baldacci F, Vergallo A, Del Dotto P, Ulivi M, Palombo C, Casolo G, Bonuccelli U. RE response to: «Entacapone, Parkinson’s disease, «functional adrenergic denervation», and Takotsubo syndrome». Parkinsonism Relat Disord. 2015;21(4):427. https://doi.org/10.1016/j.parkreldis.2014.11.010
21. Shinmura K. Cardiac Senescence, Heart Failure, and Frailty: A Triangle in Elderly People. Keio J Med. 2016;65(2):25–32. https://doi.org/10.2302/kjm.2015-0015-IR
22. Goldstein DS, Holmes C, Cannon RO, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med. 1997;336(10):696–702. https://doi.org/10.1056/NEJM199703063361004
23. Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y. Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases. J Clin Invest. 2024;134(1):e172460. https://doi.org/10.1172/JCI172460
24. Palma JA, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clin Geriatr Med. 2020;36(1):53–67. https://doi.org/10.1016/j.cger.2019.09.002
25. Zalyalova ZA, Khasanova DM, Ilina GR. Orthostatic hypotension in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(6):16-21. (Russian) https://doi.org/10.17116/jnevro202312306116 EDN: NCZUGN.
26. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139 Suppl 1:318–324. https://doi.org/10.1111/jnc.13691
27. Longardner K, Bayram E, Litvan I. Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. Front Neurol. 2020;11:897. https://doi.org/10.3389/fneur.2020.00897
28. Chevalier G, Udovin L, Otero-Losada M, Bordet S, Capani F, Luo S, Goetz CG, Perez-Lloret S. Genetics of Neurogenic Orthostatic Hypotension in Parkinson’s Disease, Results from a Cross-Sectional In Silico Study. Brain Sci. 2023;13(3):506. https://doi.org/10.3390/brainsci13030506
29. Goldstein DS, Cheshire WP Jr. Roles of cardiac sympathetic neuroimaging in autonomic medicine. Clin Auton Res. 2018;28(4),397-410. https://doi.org/10.1007/s10286-018-0547-6
30. Yang YW, Hsieh TF, Li CI, Liu CS, Lin WY, Chiang JH, Li TC, Lin CC. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017;96(3):e5921. https://doi.org/10.1097/MD.0000000000005921
31. Liu H, Xie YM, Yi DH, Wang YY. Clinical and medicine characteristics of patients with Parkinson’s syndrome. Zhongguo Zhong Yao Za Zhi. 2014;39(18):3493–3498.
32. Cuenca-Bermejo L, Almela P, Navarro-Zaragoza J, Fernández Villalba E, González-Cuello AM, Laorden ML, Herrero MT. Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence. Int J Mol Sci. 2021;22(24):13488. https://doi.org/10.3390/ijms222413488
33. Mochizuki H, Ebihara Y, Ugawa Y, Ishii N, Taniguchi A, Nagamachi S, Shiomi K, Nakazato M. PR Prolongation and Cardiac 123I-MIBG Uptake Reduction in Parkinson’s Disease. Eur Neurol. 2015;74(1-2):107–111. https://doi.org/10.1159/000439022
34. Piqueras-Flores J, López-García A, Moreno-Reig Á, González-Martínez A, Hernández-González A, Vaamonde-Gamo J, Jurado-Román A. Structural and functional alterations of the heart in Parkinson’s disease. Neurol Res. 2018;40(1):53–61. https://doi.org/10.1080/01616412.2017.1390933
35. Ozturk U, Ozturk O. Index of cardio-electrophysiological balance and Parkinson disease. Medicine (Baltimore). 2023;102(37):e35075. https://doi.org/10.1097/MD.0000000000035075
36. Heranval A, Lefaucheur R, Fetter D, Rouillé A, Le Goff F, Maltête D. Drugs with potential cardiac adverse effects: Retrospective study in a large cohort of parkinsonian patients. Rev Neurol (Paris). 2016;172(4-5):318–323. https://doi.org/10.1016/j.neurol.2015.11.007
37. Renoux C, Dell’Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson’s disease. Br J Clin Pharmacol. 2016;82(2):461–472. https://doi.org/10.1111/bcp.12964
38. Nishida N, Yoshida K, Hata Y. Sudden unexpected death in early Parkinson’s disease: neurogenic or cardiac death? Cardiovasc Pathol. 2017;30:19–22. https://doi.org/10.1016/j.carpath.2017.06.001
39. Menezes-Rodrigues FS, Menezes-Rodrigues FS, Scorza CS, Fiorini AC, Caricati-Neto A, Scorza CA, Finsterer J, Scorza FA. Sudden unexpected death in Parkinson’s disease: why is drinking water important? Neurodegener Dis Manag. 2019;9(4):241–246. https://doi.org/10.2217/nmt-2019-0010
40. Scorza FA, Cavalheiro EA, Scorza CA, Ferraz HB. Sudden unexpected death in Parkinson’s disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilepsy Behav. 2016;57(Pt A):124–125. https://doi.org/10.1016/j.yebeh.2016.01.035
41. Scorza FA, Guimarães-Marques M, Nejm M, de Almeida ACG, Scorza CA, Fiorini AC, Finsterer J. Sudden unexpected death in Parkinson’sdisease: Insights from clinical practice. Clinics (Sao Paulo). 2022;77:100001. https://doi.org/10.1016/j.clinsp.2021.100001
42. Matsumoto H, Sengoku R, Saito Y, Kakuta Y, Murayama S, Imafuku I. Sudden death in Parkinson’s disease: a retrospective autopsy study. J Neurol Sci. 2014;343(1-2):149–152. https://doi.org/10.1016/j.jns.2014.05.060
Review
For citations:
Yudina V.V., Voskresenskaya O.N. Cardiovascular disorders in Parkinson's disease. Russian neurological journal. 2024;29(6):15-19. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-6-15-19
Views:
554
Email this article 